KGET Stock Overview
Engages in the medicinal Cannabis Industry in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
CaliPharms, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 3 Year Change | 0% |
| 5 Year Change | 0% |
| Change since IPO | -99.98% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| KGET | US Machinery | US Market | |
|---|---|---|---|
| 7D | 0% | 0.5% | 1.2% |
| 1Y | 0% | 12.2% | 21.0% |
Return vs Industry: KGET underperformed the US Machinery industry which returned 12.5% over the past year.
Return vs Market: KGET underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| KGET volatility | |
|---|---|
| KGET Average Weekly Movement | n/a |
| Machinery Industry Average Movement | 4.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 18.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: KGET's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine KGET's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Eric Watson | n/a |
CaliPharms, Inc. engages in the medicinal Cannabis Industry in the United States. It focuses on the THC and CBD beverage industry. The company was formerly known as Kleangas Energy Technologies, Inc. and changed its name to CaliPharms, Inc. in January, 2017.
CaliPharms, Inc. Fundamentals Summary
| KGET fundamental statistics | |
|---|---|
| Market cap | US$13.88k |
| Earnings (TTM) | -US$6.31m |
| Revenue (TTM) | US$112.47k |
0.0x
P/S Ratio0.0x
P/E RatioIs KGET overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KGET income statement (TTM) | |
|---|---|
| Revenue | US$112.47k |
| Cost of Revenue | US$143.03k |
| Gross Profit | -US$30.57k |
| Other Expenses | US$6.28m |
| Earnings | -US$6.31m |
Last Reported Earnings
Sep 30, 2014
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did KGET perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/10 10:00 |
| End of Day Share Price | 2025/02/10 00:00 |
| Earnings | 2014/09/30 |
| Annual Earnings | 2013/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CaliPharms, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.